Beam Therapeutics
Vice President, Clinical Pharmacology
Biography:
Bahru Habtemariam, PharmD, is currently the Vice President of Clinical Pharmacology at Beam Therapeutics where he is responsible for designing and deploying clinical pharmacology and early clinical development strategies across therapeutic areas. Prior to Beam, Dr. Habtemariam was Senior Director of Clinical Pharmacology at Alnylam Pharmaceuticals where he played a pivotal role in successful development of multiple drugs from Phase 1 to approval in record time. Prior to Alnylam, Dr. Habtemariam was a clinical Pharmacology reviewer and Team Leader at the FDA where he spent 9 years supporting Hematology and Oncology disease areas. Dr. Habtemariam started his biopharma career at Novartis, where he worked in the Modeling and Simulation group supporting the development of oncology, immunology, and cardiovascular drugs. Before entering biopharma, he completed a 2-year clinical pharmacology and drug development fellowship at Cognigen Corporation and at the University at Buffalo. Dr. Habtemariam began his scientific career in computational chemistry conducting computer aided drug design and molecular dynamics simulations while enrolled in the Pharm.D. program at the University of Maryland School of Pharmacy.
Speaker In:
-
Educational Session – The Art of The Possible - 25 September 2024 (5:45 pm - 6:45 pm)
